Between 1995 and 2005 the company advertised the drug as a treatment for depression, anxiety, irritability, disrupted sleep, nausea and gambling addiction, through an ad campaign called "Viva Zyprexa," according to a presser from the AG's office.
Turns out that the FDA had not approved the drug for any of the above uses.
During the campaign, Lilly provided incentives to doctors to proscribe Zyprexa for children and adolescents(!) in unapproved dosage amounts.
"None of these uses were medically acceptable for reimbursement by state Medicaid programs," says the AG's office.
There is also a criminal case pending in the U.S. Eastern District Court, charging Lilly with a misdemeanor violation of the Food, Drug and Cosmetic Act. In a plea agreement, the company has agreed to pay a $615 million "criminal fine."
That's an expensive misdemeanor!